MATTHEW OSBORNE: Open Payments
NPI 1821538653 · PORT CHARLOTTE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,046 in 118 payments from 20 companies in 2025. Trend: 2023 $1,511 · 2024 $1,546 · 2025 $2,046
Food & beverage: $2,046
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $424 |
| Novo Nordisk Inc | 20 | $344 |
| PFIZER INC. | 12 | $267 |
| Amgen Inc. | 15 | $213 |
| GlaxoSmithKline, LLC. | 21 | $154 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $114 |
| Astellas Pharma US Inc | 5 | $113 |
| Esperion Therapeutics, Inc. | 6 | $111 |
| Aimmune Therapeutics, Inc. | 3 | $51 |
| IBSA Pharma Inc. | 2 | $43 |
Products named: NURTEC ODT, VRAYLAR, QULIPTA, Ozempic, TRELEGY ELLIPTA, EVENITY, Wegovy, CAPLYTA.
Industry payments across FL — which companies pay providers there.
